Onkologie. 2024:18(2):92-97 | DOI: 10.36290/xon.2024.017
Current targeted therapy options in chronic lymphocytic leukemia
- I. interní klinika - hematologie, Všeobecná fakultní nemocnice a 1. LF UK, Praha
The treatment of chronic lymphocytic leukemia (CLL) has undergone profound changes in the last decade with significant improvements in therapeutic outcomes and longer survival of patients with this disease. A major change has been the advent of targeted drugs, especially Bruton's tyrosine kinase inhibitors (acalabrutinib, ibrutinib, zanubrutinib) and Bcl2 inhibitors (venetoclax). These small molecules have already practically replaced chemotherapy in routine practice, first in relapse setting and more recently in first-line treatment of CLL. The main advantages of targeted therapy include better tolerance to treatment and high efficacy, including in the group of patients with prognostically unfavourable TP53 gene aberrations, who were usually refractory to chemotherapy. This article summarizes the current options for targeted therapy and the main trends in CLL treatment.
Keywords: chronic lymphocytic leukemia, BTK inhibitors, Bcl2 inhibitory.
Accepted: April 19, 2024; Published: May 3, 2024 Show citation
References
- Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
Go to original source... 
Go to PubMed... - Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36(4):1171-1175. Go to original source... Go to PubMed...
- Ghia P, Pluta A, Wach M, et al. Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 2022;6(12):E801. Go to original source... Go to PubMed...
- Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J. Clin. Oncol. 2021;39(31):3441-3452. Go to original source... Go to PubMed...
- Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am. J. Hematol. 2019;94(12):1353-1363. Go to original source... Go to PubMed...
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2014;370(11):997-1007. Go to original source... Go to PubMed...
- Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet. Oncol. 2020;21(9):1188-1200. Go to original source... Go to PubMed...
- Eichhorst B, Niemann CU, Kater AP, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2023;388(19):1739-1754. Go to original source... Go to PubMed...
- Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839-850. Go to original source... Go to PubMed...
- Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet. Oncol. 2022;23(8):1031-1043. Go to original source... Go to PubMed...
- Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2023;388(4):319-332. Go to original source... Go to PubMed...
- Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet. Haematol. 2023;10(1):e35-e45. Go to original source... Go to PubMed...
- Kater AP, Owen C, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid. 2022;1(7). Go to original source... Go to PubMed...
- Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278-3289. Go to original source... Go to PubMed...
- Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2023;389(1):33-44. Go to original source... Go to PubMed...